After hours: February 4 at 6:00:46 PM EST Loading Chart for VIR ...

Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various ...

Shares of Vir Biotechnology (NASDAQ:VIR) climbed ~42% in the premarket on Wednesday after the company posted initial Phase 1 data for two antitumor agents developed using its PRO-XTEN masking ...

VIR-5818 showed 50% tumor shrinkage in HER2-positive cancers and 33% partial responses in heavily pretreated CRC patients. VIR-5500 achieved PSA reductions in 100% of prostate cancer patients ...

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of $110.00. Discover outperforming stocks and invest ...

Vir Sanghvi is a print and television journalist, and talk show host. He tweets @virsanghvi ...

Vir Singh Negi, currently serving as Executive Director of All India Institute of Medical Sciences, Bilaspur, has been appointed as the Director of Jawaharlal Institute of Postgraduate Medical ...